J
Jonathan D. Schoenfeld
Researcher at Brigham and Women's Hospital
Publications - 146
Citations - 4666
Jonathan D. Schoenfeld is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Radiation therapy & Cancer. The author has an hindex of 29, co-authored 123 publications receiving 2917 citations. Previous affiliations of Jonathan D. Schoenfeld include University of Cambridge & Yale University.
Papers
More filters
Journal ArticleDOI
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa,Omoruyi Credit Irabor,Jonathan D. Schoenfeld,Jürgen Hesser,Sandra Demaria,Silvia C. Formenti +5 more
TL;DR: Evidence for this growing consensus is that combining radiotherapy with immunotherapy provides an opportunity to boost abscopal response rates, extending the use of radiotherapy to treatment of both local and metastatic disease and emerging limitations are highlighted.
Journal ArticleDOI
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab
Ravi A. Chandra,Tyler J. Wilhite,Tracy A. Balboni,Brian M. Alexander,Alexander Spektor,Patrick A. Ott,Andrea K. Ng,F. Stephen Hodi,Jonathan D. Schoenfeld +8 more
TL;DR: A systematic review of melanoma patients treated with radiotherapy and ipilimumab suggests that a subset of patients may have more favorable out-of-field responses following treatment with radiation, and finds that multiple fraction radiation regimens were associated with a more favorable response.
Journal ArticleDOI
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Glenn J. Hanna,Patrick H. Lizotte,Megan E. Cavanaugh,Frank C. Kuo,Priyanka Shivdasani,Alexander Frieden,Nicole G. Chau,Jonathan D. Schoenfeld,Jochen H. Lorch,Ravindra Uppaluri,Laura E. MacConaill,Laura E. MacConaill,Robert I. Haddad +12 more
TL;DR: Somatic frameshift events in tumor suppressor genes and higher TMB among virus-negative SCCHN tumors predict anti-PD-1/L1 response.
Journal ArticleDOI
Is everything we eat associated with cancer? A systematic cookbook review
TL;DR: The conclusions, statistical significance, and reproducibility in the literature on associations between specific foods and cancer risk were examined, and associations with cancer risk or benefits have been claimed for most food ingredients.
Journal ArticleDOI
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Jonathan D. Schoenfeld,Jonathan D. Schoenfeld,Glenn J. Hanna,Glenn J. Hanna,Vickie Y. Jo,Bhupendra Rawal,Yu-Hui Chen,P.S. Catalano,Ana Lako,Ana Lako,Zoe B. Ciantra,Jason L. Weirather,Shana Criscitiello,Shana Criscitiello,Adrienne M. Luoma,Nicole G. Chau,Jochen H. Lorch,Jochen H. Lorch,Jason I. Kass,Jason I. Kass,Donald J. Annino,Donald J. Annino,Laura A. Goguen,Laura A. Goguen,Anupam M. Desai,Brendan Ross,Brendan Ross,Hina Shah,Heather A. Jacene,Danielle N. Margalit,Danielle N. Margalit,Roy B. Tishler,Roy B. Tishler,Kai W. Wucherpfennig,Scott J. Rodig,Scott J. Rodig,Ravindra Uppaluri,Ravindra Uppaluri,Robert I. Haddad,Robert I. Haddad +39 more
TL;DR: Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity and promising rates of response in both arms are observed, supporting further neoadjuvant studies with these agents.